ClarityCare has raised $16.5 million in an oversubscribed Series A round led by Headline, a financing that the company is tying directly to the operational pressure building around prior authorization. The startup said total funding now stands at $19.8 million, and that it will use the new capital to expand its sales and engineering team, develop new products, and grow its healthcare footprint, particularly in the government sector.
The company’s pitch arrives as payers work toward compliance with CMS-0057-F, a January 2026 rule from the Centers for Medicare and Medicaid Services. Payers have until January 1, 2027 to meet the rule’s requirements, including a 72-hour decision timeframe for expedited prior authorization requests and seven days for standard requests.
Why the timing matters
Prior authorization has long been a staffing and workflow problem as much as a clinical one. ClarityCare points to a report from the American Medical Association saying clinics can spend up to two business days per week on related work, including gathering medical records, checking plan-specific eligibility and policies, and filing paperwork. The AMA has described the process as overused, costly, inefficient, opaque and responsible for patient care delays, while calling for more automation.
That makes the new federal deadlines more than a compliance exercise. They compress turnaround expectations for organizations already dealing with growing volumes and limited staffing, creating an opening for vendors that can take friction out of the administrative steps around review.
ClarityCare CEO Hermine Tranie said Medicaid and Medicare Advantage plans face the most pressure from the new CMS rules, while adding that the company is also growing with commercial plans across medical management and cost containment operations.
Product and early operating signals
ClarityCare’s product centers on an AI agent called Electra, which the company said is designed to streamline prior authorization by handling administrative work, supporting clinical review with summaries and recommendations, and completing paperwork after a clinician makes a decision. Tranie said existing tools tend to address only one slice of the process, such as rules-based auto-approval for simple procedure codes or record summarization after documents have already been collected.
The company said Electra can approve and escalate requests but will never issue denials, and that the tool includes a human-in-the-loop to reduce erroneous decisions. That positioning matters commercially: in prior authorization, buyers may be more willing to adopt automation that shortens response times without transferring denial authority to software.
ClarityCare reported that for one of its seven current customers, Electra reduced prior authorization waits from 12 days to two. Across its customer base, the company said the workflows touched by the platform affect care for 6 million people. Those customers include health plans, third-party administrators, medical management companies, and government health services organizations supporting Medicaid and Medicare programs across the country.
The broader signal is that prior authorization automation is moving from an efficiency story to a deadline-driven procurement story. If CMS-0057-F forces payers to rework operating models on a fixed timetable, vendors that can fit into clinician-led review rather than replace it may have the clearer path to adoption.
